You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. PAR-24-066: NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44-Clinical Trial Required)

    Release Date: 11-30-2023Open Date: 12-01-2023 Due Dates: Multiple Close Date: 01-08-2027

    This Notice of Funding Opportunity (NOFO) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials related to the research mission of the NEI. This program provides support for milestone-driven, commercialization-oriented clinical trials and will involve participation of NEI program ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. RFA-TR-24-001: Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)

    Release Date: 12-01-2023Open Date: 12-04-2023 Due Dates: Multiple Close Date: 03-16-2024

    While there are thousands of rare diseases, the number of underlying etiologies is much smaller. Moreover, many disease etiologies underlie multiple traditional diseases. This is most readily seen for rare monogenic diseases, where the most common etiologies include premature termination codons, protein misfolding, and abnormal RNA splicing. Other examples of rare disease shared molecular etiologi ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. RFA-AA-24-001: High-Throughput Screening (HTS) Platform for Discovery of Medications to Treat Alcohol Use Disorder (R43/R44 Clinical Trials Not Allowed)

    Release Date: 12-21-2023Open Date: 03-05-2024Due Date: 04-09-2024Close Date: 04-10-2024

    Drug development is challenging, particularly for Central Nervous System (CNS) medications. It takes approximately 18 years to move a potential CNS medication from its initial discovery phase to the marketplace, often costing several billion dollars. The failure rate is high (only 8% of new CNS compounds entering Phase I studies will reach the market) and contributes to the high costs and slow rat ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. RFA-AA-24-002: High-Throughput Screening (HTS) Platform for Discovery of Medications to Treat Alcohol Use Disorder (R41/R42 Clinical Trials Not Allowed)

    Release Date: 12-21-2023Open Date: 03-05-2024Due Date: 04-09-2024Close Date: 04-10-2024

    Drug development is challenging, particularly for Central Nervous System (CNS) medications. It takes approximately 18 years to move a potential CNS medication from its initial discovery phase to the marketplace, often costing several billion dollars. The failure rate is high (only 8% of new CNS compounds entering Phase I studies will reach the market) and contributes to the high costs and slow rat ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. RFA-DA-24-038: Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)

    Release Date: 04-19-2023Open Date: 07-15-2023 Due Dates: Multiple Close Date: 02-15-2025

    According to the Centers for Disease Control and Prevention (CDC), more than 100,000 deaths from overdose were reported from April 2020 to April 2021 alone. Data shows an increase in overdoses due to natural and semi-synthetic opioids, synthetic opioids, predominantly fentanyl, and psychostimulants, such as methamphetamine or cocaine. In fact, in the year ending in April 2021, fentanyl was the lea ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. N241-D04: Direct to Phase II: Next-generation Autonomy for Unmanned Maritime Vehicles (UMVs)

    Release Date: 10-03-2023Open Date: 01-31-2024Due Date: 03-31-2025Close Date: 03-04-2024

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Trusted AI and Autonomy The technology within this topic is restricted under the International Traffic in Arms Regulation (ITAR), 22 CFR Parts 120-130, which controls the export and import of defense-related material and services, including export of sensitive technical data, or the Export Administration Regulation (EAR), 15 CFR Parts 730-774, which cont ...

    SBIRPhase I/Phase IIDepartment of DefenseNavy
  7. SOCOM244-004: Handheld Kinetic Defeat of UAS

    Release Date: 10-03-2023Open Date: 01-30-2024Due Date: 03-31-2025Close Date: 03-04-2024

    OBJECTIVE: The objective of this topic is to develop a handheld defeat capability to defeat Unmanned/Uncrewed Aircraft Systems (UAS). Low size, weight, power, and cost (SWaP-C) solutions that can kinetically defeat Group 1-3 UAS (DoD defined) are desired. Defeat range is important, but reliability and a high probability of kill (Pk) are higher priority. IMPORTANT: For SOCOM instructions: plea ...

    SBIRPhase I/Phase IIDepartment of DefenseSpecial Operations Command
  8. HR0011SB20244-01: Advanced Enabling High-Speed Technologies

    Release Date: 10-03-2023Open Date: 02-05-2024Due Date: 03-31-2025Close Date: 03-06-2024

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Hypersonics The technology within this topic is restricted under the International Traffic in Arms Regulation (ITAR), 22 CFR Parts 120-130, which controls the export and import of defense-related material and services, including export of sensitive technical data, or the Export Administration Regulation (EAR), 15 CFR Parts 730-774, which controls dual us ...

    SBIRPhase I/Phase IIDepartment of DefenseDefense Advanced Research Projects Agency
  9. A244-P006: xTechScalable AI

    Release Date: 10-03-2023Open Date: 03-18-2024Due Date: 03-31-2025Close Date: 04-17-2024

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Trusted AI and Autonomy; Advanced Computing and Software; Human-Machine Interfaces OBJECTIVE: xTechScalable AI is seeking novel, disruptive concepts and technology solutions that can assist in tackling the Army’s current needs and apply to current Army concepts. Current Machine Learning pipelines are vulnerable to manipulation of code, data, labels, and ...

    SBIRPhase I/Phase IIDepartment of DefenseArmy
  10. HHS-2024-ACL-NIDILRR-BISB-0070: Small Business Innovation Research Program (SBIR) Phase II

    Release Date: 01-05-2024Open Date: 01-05-2024Due Date: 03-05-2024Close Date: 03-05-2024

    The purpose of the Federal SBIR program is to stimulate technological innovation in the private sector, strengthen the role of small business in meeting Federal research or research and development (R/R&D) needs, and improve the return on investment from Federally-funded research for economic and social benefits to the nation. The specific purpose of NIDILRR's SBIR program is to improve the lives ...

    SBIRPhase IIDepartment of Health and Human ServicesAdministration for Community Living
US Flag An Official Website of the United States Government